<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38544389</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of Enterovirus 71 inactivated vaccines against hand, foot, and mouth disease: A test-negative case-control study.</ArticleTitle><Pagination><StartPage>2330163</StartPage><MedlinePgn>2330163</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2330163</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2024.2330163</ELocationID><Abstract><AbstractText>The Enterovirus A71 (EV-A71) vaccine was introduced in China in December 2015 as a preventive measure against hand, foot, and mouth disease (HFMD) caused by EV-A71. However, the effectiveness of the vaccine (VE) in real-world settings needs to be evaluated. We conducted a test-negative case-control study to assess the effectiveness of EV-A71 vaccines in preventing EV-A71-associated HFMD. Children aged 6-71 months with HFMD were enrolled as participants. The case group comprised those who tested positive for EV-A71, while the control group comprised those who tested negative for EV-A71. To estimate VE, a logistic regression model was employed, adjusting for potential confounders including age, gender, and clinical severity. In total, 3223 children aged 6 to 71 months were included in the study, with 162 in the case group and 3061 in the control group. The proportion of children who received EV-A71 vaccination was significantly lower in the case group compared to the control group (<i>p</i> &lt; .001). The overall VE<sub>adj</sub> was estimated to be 90.8%. The VE<sub>adj</sub> estimates for partially and fully vaccinated children were 90.1% and 90.9%, respectively. Stratified by age group, the VE<sub>adj</sub> estimates were 88.7% for 6 to 35-month-olds and 95.5% for 36 to 71-month-olds. Regarding disease severity, the VE<sub>adj</sub> estimates were 86.3% for mild cases and 100% for severe cases. Sensitivity analysis showed minimal changes in the VE point estimates, with most changing by no more than 1% point. Our study demonstrates a high level of vaccine effectiveness against EV-A71-HFMD, especially in severe cases. Active promotion of EV-A71 vaccination is an effective strategy in preventing EV-A71 infections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yutong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Infectious Disease, National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Jinzhao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Infectious Disease, National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Fengfeng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Infectious Disease, National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Infectious Disease, National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Quanyi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Institute for the Control of Infectious and Endemic Diseases, Beijing Center for Disease Prevention and Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yanzhe</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Infectious Disease, National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yanping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Infectious Disease, National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhongjie</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Zhaorui</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Infectious Disease, National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enterovirus A71</Keyword><Keyword MajorTopicYN="N">Enterovirus A71 inactivated vaccine</Keyword><Keyword MajorTopicYN="N">hand, foot, and mouth disease</Keyword><Keyword MajorTopicYN="N">test negative design</Keyword><Keyword MajorTopicYN="N">vaccine effectiveness</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>28</Day><Hour>2</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38544389</ArticleId><ArticleId IdType="pmc">PMC10984126</ArticleId><ArticleId IdType="doi">10.1080/21645515.2024.2330163</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhang W, Huang Z, Huang M, Zeng J.. Predicting severe enterovirus 71-infected hand, foot, and mouth disease: Cytokines and Chemokines. Mediators Inflamm. 2020;2020:1–6. doi:10.1155/2020/9273241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/9273241</ArticleId><ArticleId IdType="pmc">PMC7013319</ArticleId><ArticleId IdType="pubmed">32089650</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui J, Nei T, Ren M, Liu FF, Li Y, Wang LP, Tan JB, Chang ZR, Li ZJ.. Epidemiological characteristics of fatal cases of hand, foot, and mouth disease in children under 5 years old in China, 2008–2018. Chin J Epidemiol. 2020;41(7):1041–1046. (in Chinese). doi:10.3760/cma.j.cn112338-20200114-00031.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn112338-20200114-00031</ArticleId><ArticleId IdType="pubmed">32741167</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox JA, Hiscox JA, Solomon T, Ooi M-H, Ng LFP. Immunopathogenesis and virus–host interactions of enterovirus 71 in patients with hand, foot and mouth disease. Front Microbiol. 2017;8:2249. doi:10.3389/fmicb.2017.02249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2017.02249</ArticleId><ArticleId IdType="pmc">PMC5713468</ArticleId><ArticleId IdType="pubmed">29238324</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren M, Cui J, Nie T, Liu FF, Sun JL, Zhang YW, Chang ZR. Epidemiological characteristics of severe cases of hand, foot, and mouth disease in China, 2008–2018. Chin J Epidemiol. 2020;41(11):1802–1807. (in Chinese). doi:10.3760/cma.j.cn112338-20200201-00063.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn112338-20200201-00063</ArticleId><ArticleId IdType="pubmed">33297642</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh WM, Badaruddin H, La H, Chen MIC, Cook AR. Severity and burden of hand, foot and mouth disease in Asia: a modelling study. BMJ Glob Health. 2018;3(1):e000442. doi:10.1136/bmjgh-2017-000442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2017-000442</ArticleId><ArticleId IdType="pmc">PMC5859810</ArticleId><ArticleId IdType="pubmed">29564154</ArticleId></ArticleIdList></Reference><Reference><Citation>Nhan L, Turner HC, Khanh TH, Hung NT, Lien LB, Hong NTT, Nhu LNT, Ny NTH, Nguyet LA, Thanh TT, et al. Economic burden attributed to children presenting to hospitals with hand, foot, and mouth disease in Vietnam. Open Forum Infect Dis. 2019;6(7). doi:10.1093/ofid/ofz284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofz284</ArticleId><ArticleId IdType="pmc">PMC6657964</ArticleId><ArticleId IdType="pubmed">31363772</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y, Jit M, Wu JT, Yang J, Leung K, Liao Q, Yu H. Economic costs and health-related quality of life for hand, foot and mouth disease (HFMD) patients in China. PLoS One. 2017;12(9):e0184266. doi:10.1371/journal.pone.0184266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0184266</ArticleId><ArticleId IdType="pmc">PMC5608208</ArticleId><ArticleId IdType="pubmed">28934232</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei MW, Meng FY, Wang SY, Li J, Zhang Y, Mao Q, Hu Y, Liu P, Shi N, Tao H, et al. 2-year efficacy, immunogenicity, and safety of vigoo enterovirus 71 vaccine in healthy Chinese children: a randomized open-label study. J Infect Dis. 2017;215(1):56–63. doi:10.1093/infdis/jiw502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw502</ArticleId><ArticleId IdType="pubmed">28077584</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello AM, Roshorm YM. Recent progress and advances towards developing enterovirus 71 vaccines for effective protection against human hand, foot and mouth disease (HFMD). Biologicals. 2022;79:1–9. doi:10.1016/j.biologicals.2022.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biologicals.2022.08.007</ArticleId><ArticleId IdType="pubmed">36089444</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818–828. doi:10.1056/NEJMoa1304923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Li Y, Wang L, Xu L, Li KL, Zeng G, An ZJ. Validation of a test-negative design case-control study for evaluating the effectiveness of enterovirus 71 inactivated vaccine. Chin J Vaccines Immun.2022;28(1):41–45. (in Chinese)</Citation></Reference><Reference><Citation>Wang X, An Z, Huo D, Jia L, Li J, Yang Y, Liang Z, Wang Q, Wang H. Enterovirus A71 vaccine effectiveness in preventing enterovirus A71 infection among medically-attended hand, foot, and mouth disease cases, Beijing, China. Hum Vaccines Immunother. 2019;15(5):1183–1190. doi:10.1080/21645515.2019.1581539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2019.1581539</ArticleId><ArticleId IdType="pmc">PMC6605830</ArticleId><ArticleId IdType="pubmed">30779680</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Zhou Y, Cheng Y, Wu P, Zhou C, Cui P, Song C, Liang L, Wang F, Qiu Q, et al. Effectiveness of EV-A71 vaccination in prevention of paediatric hand, foot, and mouth disease associated with EV-A71 virus infection requiring hospitalisation in Henan, China, 2017–18: a test-negative case-control study. Lancet Child Adolesc Health. 2019;3(10):697–704. doi:10.1016/S2352-4642(19)30185-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(19)30185-3</ArticleId><ArticleId IdType="pmc">PMC8713082</ArticleId><ArticleId IdType="pubmed">31375313</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L, Wang J, Zhang C, He W, Mo J, Zeng J, Chen M, Tan Y, Ning C. Effectiveness of enterovirus A71 vaccine in severe hand, foot, and mouth disease cases in Guangxi, China. Vaccine. 2020;38(7):1804–1809. doi:10.1016/j.vaccine.2019.12.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.12.025</ArticleId><ArticleId IdType="pubmed">31892446</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Cao L, Li Y, Hu YX, Tang L, Li KL, Yin ZD, An ZJ. Analysis of the vaccination status of enterovirus type 71 inactivated vaccine in China from 2017 to 2021. Chin J Epidemiol. 2023;44(4):561–567. (in Chinese). doi:10.3760/cma.j.cn112338-20220811-00704.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn112338-20220811-00704</ArticleId><ArticleId IdType="pubmed">37147826</ArticleId></ArticleIdList></Reference><Reference><Citation>National Health Commission of the People’s Republic of China . Hand-foot-and-mouth disease treatment guide (2018 edition). Infect Dis Inf. 2018;31(3):193–198. (in Chinese)</Citation></Reference><Reference><Citation>Yang B, Liu F, Liao Q, Wu P, Chang Z, Huang J, Long L, Luo L, Li Y, Leung GM, et al. Epidemiology of hand, foot and mouth disease in China, 2008 to 2015 prior to the introduction of EV-A71 vaccine. Euro Surveill. 2017;22(50). doi:10.2807/1560-7917.ES.2017.22.50.16-00824.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2017.22.50.16-00824</ArticleId><ArticleId IdType="pmc">PMC5743100</ArticleId><ArticleId IdType="pubmed">29258646</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Pan H, Wang X, Zhu Q, Ge Y, Cai J, Li Y, Xia A, Hu J, Zeng M. Epidemiological surveillance of hand, foot and mouth disease in Shanghai in 2014–2016, prior to the introduction of the enterovirus 71 vaccine. Emerg Microbes Infect. 2018;7(1):1–7. doi:10.1038/s41426-018-0035-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-018-0035-z</ArticleId><ArticleId IdType="pmc">PMC5861114</ArticleId><ArticleId IdType="pubmed">29559626</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li X-L, Mao Q-Y, Tao H, Zhang Y-T, Yao X, Chu K, Chen Q-H, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2013;381(9882):2024–2032. doi:10.1016/S0140-6736(13)61049-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao Y, Jin P, Zhu F. Meta-analysis on effectiveness of live attenuated influenza vaccine against seasonal influenza in children. Chin J Epidemiol. 2020;41(1):103–110. (in Chinese). doi:10.3760/cma.j.issn.0254-6450.2020.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.0254-6450.2020.01.019</ArticleId><ArticleId IdType="pubmed">32062951</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu W, Zeng G, Hu YM, Hu Y-S, Zhang Y, Hu Y-L, Wang Y, Li J-X, Zhu F-C. A comparative analysis of immunogenicity and safety of an enterovirus 71 vaccine between children aged 3–5 years and infants aged 6–35 months. Expert Rev Vaccines. 2018;17(3):257–262. doi:10.1080/14760584.2018.1430572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2018.1430572</ArticleId><ArticleId IdType="pubmed">29363365</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan SG, Feng S, Cowling BJ. Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review. Expert Rev Vaccines. 2014;13(12):1571–1591. doi:10.1586/14760584.2014.966695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2014.966695</ArticleId><ArticleId IdType="pmc">PMC4277796</ArticleId><ArticleId IdType="pubmed">25348015</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>